Semaglutide for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease
[ID6635]
Awaiting development
Reference number: GID-TA11847
Expected publication date: TBC
For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme.
As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.